GrifolsGRFS -3.48%84 9-Day RSI is 41.91 as of Jun. 30, 2026. GuruFocus rates GRFS with a GF Score™ of 84/100 and a GF Value™ of $8.92 (Modestly Undervalued). The stock has 6 warning signs investors should review. Among 1,046 Drug Manufacturers companies, Grifols ranks better than 57.46% on this metric.
The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 9-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.
As of today (2026-06-30), Grifols's 9-Day RSI is 41.91.
The industry rank for Grifols's 9-Day RSI or its related term are showing as below:
GRFS's 9-Day RSI is ranked better than 57.46% of 1046
companies
in the Drug Manufacturers industry
Industry Median: 48.085
vs GRFS: 41.91
Grifols (NAS:GRFS) 9-Day RSI Explanation
The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.
Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.
RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 9-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.
Grifols 9-Day RSI Related Terms
GRFS vs LLY, JNJ, ABBV: 9-Day RSI Comparison
For the Drug Manufacturers - General subindustry, Grifols's 9-Day RSI, along with its competitors' market caps and 9-Day RSI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Grifols 9-Day RSI vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Grifols's 9-Day RSI distribution charts can be found below:
* The bar in red indicates where Grifols's 9-Day RSI falls into.
* Note that the formula uses a positive value for the average loss.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Grifols (GRFS) has a 9-Day RSI of 41.91 as of Jun. 30, 2026. According to the industry distribution chart, Grifols ranks #445 out of 1046 companies in the Drug Manufacturers industry, placing it in the top 42.5%.
Is Grifols' 9-Day RSI too high?
Grifols' current 9-Day RSI is 41.91. The Drug Manufacturers industry median 9-Day RSI is 48.09. Grifols' value of 41.91 is 12.8% below this industry median. Based on the distribution chart, Grifols ranks #445 out of 1046 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Grifols has a GF Score™ of 84/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Grifols' 9-Day RSI compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Grifols ranks #445 out of 1046 companies for 9-Day RSI. This puts Grifols in the upper half of its industry. The industry median 9-Day RSI is 48.09. Grifols' value of 41.91 is 12.8% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 9-Day RSI for a Drug Manufacturers company?
The median 9-Day RSI among Drug Manufacturers companies is 48.09, based on 1,046 companies in the industry. Companies in the top quartile (top 25%) have a 9-Day RSI significantly above this median, while those in the bottom quartile fall well below. However, 9-Day RSI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Grifols's current 9-Day RSI of 41.91 is 12.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 9-Day RSI mean?
A high 9-Day RSI can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median 9-Day RSI is 48.09 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Grifols's current 9-Day RSI is 41.91. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Grifols stock overvalued right now?
Based on GuruFocus' analysis, Grifols (GRFS) is currently considered Modestly Undervalued. The stock's GF Value™ is $8.92, compared to a current price of $7.08 — trading 20.6% below its estimated fair value. The current 9-Day RSI is 41.91 and 12.8% below the Drug Manufacturers industry median of 48.09. Grifols' overall GF Score™ is 84/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 9-Day RSI calculated?
9-Day RSI is calculated from a company's financial statements. For Grifols (GRFS), the current 9-Day RSI is 41.91 as of Jun. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Grifols (GRFS) Overvalued in 2026?
Based on GuruFocus' analysis, Grifols stock appears to be undervalued.
The current stock price of $7.08 is trading 20.6% below its estimated GF Value™ of $8.92.
GuruFocus considers Grifols to be Modestly Undervalued.
Key valuation signals for GRFS:
9-Day RSI: 41.91
GF Value™: $8.92 vs. price of $7.08 (20.6% below fair value)
Industry Position: 12.8% below the Drug Manufacturers median (#445 of 1046)
No single metric tells the full story. See the GRFS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Grifols SA is a healthcare company engaged in activities related to plasma-derived products and diagnostic solutions. The group has four reportable segments: Biopharma, Diagnostic, Bio Supplies, and Others. The Biopharma segment focuses on products derived from human plasma for therapeutic use, while the Diagnostic segment includes the marketing of diagnostic testing equipment and reagents. The Bio Supplies segment covers biological products for non-therapeutic use and plasma sales to third parties, and the Others segment includes manufacturing services, research activities, and complementary pharmaceutical products.
84GF Score
Get the complete analysis for GRFS
9-Day RSI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
GRFS has been successfully added to your 